In December 2020, the FDA approved Orgovyx to treat advanced prostate cancer. The findings were based on the HERO clinical trial of more than 900 men. Data from this trial showed the new therapy was safer than standard androgen deprivation treatment for men with advanced prostate cancer and risk of cardiovascular disease. (2/18/21)
Este artículo está disponible en español.
The following are studies looking at androgen deprivation therapy in people with prostate cancer:
A number of other clinical trials for patients with prostate cancer can be found here.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.